Literature DB >> 24733613

[Multimodal management in soft tissue sarcoma of the trunk and extremities].

M P H Ghadimi1, A Rehders, W T Knoefel.   

Abstract

Soft tissue sarcoma (STS) is a rare, extremely heterogeneous group of malignant tumors of mesodermal origin. With an incidence of 1-5 per 100,000/year they account for only 1 % of all human malignancies. The STSs occur predominantly in the lower extremities and the trunk. To date 100 different histopathological subentities can be defined. The prognosis varies substantially depending on the localization and histology. Whereas local recurrence rates and overall survival of sarcomas of the extremities have benefited from the introduction of multimodal therapies, only marginal progress has been made in the management of trunk STSs. This manuscript gives an overview of preoperative diagnostics, pathology and neoadjuvant as well as adjuvant therapeutic options for soft tissue sarcoma.

Entities:  

Mesh:

Year:  2014        PMID: 24733613     DOI: 10.1007/s00104-013-2690-x

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  19 in total

Review 1.  A systematic review and meta-analysis of oncologic outcomes of pre- versus postoperative radiation in localized resectable soft-tissue sarcoma.

Authors:  Emad Al-Absi; Forough Farrokhyar; Rajrish Sharma; Kaitlyn Whelan; Tom Corbett; Malti Patel; Michelle Ghert
Journal:  Ann Surg Oncol       Date:  2010-03-09       Impact factor: 5.344

2.  Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group.

Authors:  E Stoeckle; J M Coindre; S Bonvalot; G Kantor; P Terrier; F Bonichon; B Nguyen Bui
Journal:  Cancer       Date:  2001-07-15       Impact factor: 6.860

Review 3.  Cancer treatment and survivorship statistics, 2012.

Authors:  Rebecca Siegel; Carol DeSantis; Katherine Virgo; Kevin Stein; Angela Mariotto; Tenbroeck Smith; Dexter Cooper; Ted Gansler; Catherine Lerro; Stacey Fedewa; Chunchieh Lin; Corinne Leach; Rachel Spillers Cannady; Hyunsoon Cho; Steve Scoppa; Mark Hachey; Rebecca Kirch; Ahmedin Jemal; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2012-06-14       Impact factor: 508.702

4.  Randomized trial of cytoreduction followed by intraperitoneal chemotherapy versus cytoreduction alone in patients with peritoneal sarcomatosis.

Authors:  S Bonvalot; A Cavalcanti; C Le Péchoux; P Terrier; D Vanel; J Y Blay; A Le Cesne; D Elias
Journal:  Eur J Surg Oncol       Date:  2005-10       Impact factor: 4.424

Review 5.  Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults.

Authors: 
Journal:  Cochrane Database Syst Rev       Date:  2000

6.  Effect of radiation therapy on survival in surgically resected retroperitoneal sarcoma: a propensity score-adjusted SEER analysis.

Authors:  A H Choi; J S Barnholtz-Sloan; J A Kim
Journal:  Ann Oncol       Date:  2012-02-09       Impact factor: 32.976

Review 7.  Advances in magnetic resonance imaging of musculoskeletal tumours.

Authors:  J-L Drapé
Journal:  Orthop Traumatol Surg Res       Date:  2013-02-04       Impact factor: 2.256

8.  Phase 2 study of preoperative image-guided intensity-modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft tissue sarcoma.

Authors:  Brian O'Sullivan; Anthony M Griffin; Colleen I Dickie; Michael B Sharpe; Peter W M Chung; Charles N Catton; Peter C Ferguson; Jay S Wunder; Benjamin M Deheshi; Lawrence M White; Rita A Kandel; David A Jaffray; Robert S Bell
Journal:  Cancer       Date:  2013-02-19       Impact factor: 6.860

Review 9.  Increasing incidence rates of soft tissue sarcomas? A population-based epidemiologic study and literature review.

Authors:  C Wibmer; A Leithner; N Zielonke; M Sperl; R Windhager
Journal:  Ann Oncol       Date:  2009-10-25       Impact factor: 32.976

10.  The role of multimodality therapy in soft-tissue sarcoma.

Authors:  M F Brennan; E S Casper; L B Harrison; M H Shiu; J Gaynor; S I Hajdu
Journal:  Ann Surg       Date:  1991-09       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.